Which has higher valuation and earnings, CMMB or DWTX?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A Dogwood Therapeutics N/A N/A -$34.26M -$10.60 N/A

Is CMMB or DWTX more profitable?

Chemomab Therapeutics' return on equity of -89.03% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -89.03% -79.68% Dogwood Therapeutics N/A -108.57% -30.28%

Is HYPD or CMMB more profitable?

Chemomab Therapeutics' return on equity of -89.03% beat Hyperion DeFi's return on equity. Company Net Margins Return on Equity Return on Assets Hyperion DeFi N/A -91.59% -73.08% Chemomab Therapeutics N/A -89.03% -79.68%

Which has preferable earnings & valuation, CRVO or CMMB?

CervoMed is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CervoMed N/A N/A -$26.97M -$3.28 N/A Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A

Do analysts recommend or CMMB?

Chemomab Therapeutics has a consensus target price of $25.00, indicating a potential upside of 1,738.24%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Chemomab Therapeutics is more favorable than . Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, or CMMB?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio N/A N/A N/A N/A N/A Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A

Is or CMMB more profitable?

's return on equity of 0.00% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets N/A N/A N/A Chemomab Therapeutics N/A -89.03% -79.68%

Chemomab Therapeutics (CMMB) Competitors

$1.36 -0.04 (-2.86%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.38 +0.02 (+1.76%)

As of 07/24/2026 06:13 PM Eastern

Compare

CMMB vs. DWTX, HYPD, CRVO, FTH, and SCYX

Should you buy Chemomab Therapeutics stock or one of its competitors? MarketBeat compares Chemomab Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Chemomab Therapeutics include Dogwood Therapeutics (DWTX), Hyperion DeFi (HYPD), CervoMed (CRVO), Sensei Biotherapeutics (FTH), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry.

How does Chemomab Therapeutics compare to Dogwood Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Chemomab Therapeutics' return on equity of -89.03% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
Dogwood Therapeutics	N/A	-108.57%	-30.28%

Chemomab Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market.

Chemomab Therapeutics presently has a consensus price target of $25.00, indicating a potential upside of 1,738.24%. Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 700.00%. Given Chemomab Therapeutics' higher possible upside, analysts clearly believe Chemomab Therapeutics is more favorable than Dogwood Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

46.0% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Dogwood Therapeutics had 2 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 3 mentions for Dogwood Therapeutics and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.89 beat Dogwood Therapeutics' score of 0.62 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Chemomab Therapeutics	Very Positive
Dogwood Therapeutics	Positive

Summary

Chemomab Therapeutics beats Dogwood Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Hyperion DeFi?

Hyperion DeFi (NASDAQ:HYPD) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Hyperion DeFi presently has a consensus target price of $6.95, indicating a potential upside of 176.89%. Chemomab Therapeutics has a consensus target price of $25.00, indicating a potential upside of 1,738.24%. Given Chemomab Therapeutics' higher possible upside, analysts plainly believe Chemomab Therapeutics is more favorable than Hyperion DeFi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Hyperion DeFi has a beta of 2.49, meaning that its share price is 149% more volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Chemomab Therapeutics' return on equity of -89.03% beat Hyperion DeFi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-91.59%	-73.08%
Chemomab Therapeutics	N/A	-89.03%	-79.68%

Chemomab Therapeutics has lower revenue, but higher earnings than Hyperion DeFi. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Hyperion DeFi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$1.04M	36.48	-$45.31M	-$9.95	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

25.8% of Hyperion DeFi shares are owned by institutional investors. Comparatively, 46.0% of Chemomab Therapeutics shares are owned by institutional investors. 7.5% of Hyperion DeFi shares are owned by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Hyperion DeFi and Hyperion DeFi both had 1 articles in the media. Chemomab Therapeutics' average media sentiment score of 1.89 beat Hyperion DeFi's score of 1.87 indicating that Chemomab Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Hyperion DeFi	Very Positive
Chemomab Therapeutics	Very Positive

Summary

Chemomab Therapeutics beats Hyperion DeFi on 7 of the 13 factors compared between the two stocks.

How does Chemomab Therapeutics compare to CervoMed?

CervoMed (NASDAQ:CRVO) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

25.1% of CervoMed shares are owned by institutional investors. Comparatively, 46.0% of Chemomab Therapeutics shares are owned by institutional investors. 35.8% of CervoMed shares are owned by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CervoMed has a beta of -0.68, indicating that its stock price is 168% less volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

CervoMed presently has a consensus price target of $22.60, indicating a potential upside of 749.62%. Chemomab Therapeutics has a consensus price target of $25.00, indicating a potential upside of 1,738.24%. Given Chemomab Therapeutics' higher probable upside, analysts plainly believe Chemomab Therapeutics is more favorable than CervoMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, CervoMed had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 2 mentions for CervoMed and 1 mentions for Chemomab Therapeutics. CervoMed's average media sentiment score of 1.89 equaled Chemomab Therapeutics'average media sentiment score.

Company	Overall Sentiment
CervoMed	Very Positive
Chemomab Therapeutics	Very Positive

CervoMed is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CervoMed	N/A	N/A	-$26.97M	-$3.28	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

Chemomab Therapeutics has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Chemomab Therapeutics' return on equity of -89.03% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CervoMed	-672.80%	-136.08%	-112.62%
Chemomab Therapeutics	N/A	-89.03%	-79.68%

Summary

Chemomab Therapeutics beats CervoMed on 9 of the 13 factors compared between the two stocks.

How does Chemomab Therapeutics compare to ?

(:) and Chemomab Therapeutics (NASDAQ:CMMB) are related companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, had 1160 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 1161 mentions for and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.89 beat 's score of 0.00 indicating that Chemomab Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
	Neutral
Chemomab Therapeutics	Very Positive

46.0% of Chemomab Therapeutics shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
	N/A	N/A	N/A
Chemomab Therapeutics	N/A	-89.03%	-79.68%

Chemomab Therapeutics has a consensus target price of $25.00, indicating a potential upside of 1,738.24%. Given Chemomab Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Chemomab Therapeutics is more favorable than .

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
	N/A	N/A	N/A	N/A	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

Summary

Chemomab Therapeutics beats on 6 of the 9 factors compared between the two stocks.

How does Chemomab Therapeutics compare to SCYNEXIS?

Chemomab Therapeutics (NASDAQ:CMMB) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

46.0% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Chemomab Therapeutics has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

In the previous week, Chemomab Therapeutics and Chemomab Therapeutics both had 1 articles in the media. Chemomab Therapeutics' average media sentiment score of 1.89 beat SCYNEXIS's score of 1.87 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Chemomab Therapeutics	Very Positive
SCYNEXIS	Very Positive

SCYNEXIS has higher revenue and earnings than Chemomab Therapeutics. SCYNEXIS is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A
SCYNEXIS	$20.60M	1.80	-$8.61M	-$3.84	N/A

Chemomab Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-89.03%	-79.68%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Chemomab Therapeutics currently has a consensus target price of $25.00, indicating a potential upside of 1,738.24%. SCYNEXIS has a consensus target price of $24.00, indicating a potential upside of 543.43%. Given Chemomab Therapeutics' higher possible upside, equities analysts clearly believe Chemomab Therapeutics is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Chemomab Therapeutics and SCYNEXIS tied by winning 6 of the 12 factors compared between the two stocks.

Get Chemomab Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMMB vs. The Competition

Export

Metric	Chemomab Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.79M	$3.67B	$6.87B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-0.61	21.48	27.14	23.64
Price / Sales	N/A	170.08	517.06	88.99
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	0.68	7.88	10.28	6.07
Net Income	-$8.99M	$23.86M	$3.60B	$331.99M
7 Day Performance	-12.82%	-3.82%	-1.27%	-0.63%
1 Month Performance	-12.82%	-2.61%	-0.37%	-2.00%
1 Year Performance	-68.81%	32.79%	18.30%	13.62%

Chemomab Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMMB Chemomab Therapeutics	3.1573 of 5 stars	$1.36 -2.9%	$25.00 +1,738.2%	-68.8%	$9.79M	N/A	N/A	20	Positive News Gap Up
DWTX Dogwood Therapeutics	3.0278 of 5 stars	$1.43 +3.6%	$12.00 +739.2%	-68.3%	$46.41M	N/A	N/A	5
HYPD Hyperion DeFi	3.17 of 5 stars	$2.96 -0.3%	$6.95 +134.8%	-69.3%	$45.02M	$810K	N/A	40
CRVO CervoMed	3.6118 of 5 stars	$3.08 -6.9%	$22.60 +633.8%	-67.0%	$44.77M	$4.01M	N/A	4	News Coverage
FTH Sensei Biotherapeutics	4.1284 of 5 stars	$33.12 -0.7%	$58.50 +76.6%	N/A	$44.77M	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMMB) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemomab Therapeutics (CMMB) Competitors

CMMB vs. DWTX, HYPD, CRVO, FTH, and SCYX

How does Chemomab Therapeutics compare to Dogwood Therapeutics?

Summary

How does Chemomab Therapeutics compare to Hyperion DeFi?

Summary

How does Chemomab Therapeutics compare to CervoMed?

Summary

How does Chemomab Therapeutics compare to ?

Summary

How does Chemomab Therapeutics compare to SCYNEXIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB vs. The Competition

Chemomab Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Chemomab Therapeutics (CMMB) Competitors

CMMB vs. DWTX, HYPD, CRVO, FTH, and SCYX

How does Chemomab Therapeutics compare to Dogwood Therapeutics?

Which has higher valuation and earnings, CMMB or DWTX?

Is CMMB or DWTX more profitable?

Which has more risk and volatility, CMMB or DWTX?

Do analysts recommend CMMB or DWTX?

Do institutionals and insiders hold more shares of CMMB or DWTX?

Does the media favor CMMB or DWTX?

Summary

How does Chemomab Therapeutics compare to Hyperion DeFi?

Do analysts prefer HYPD or CMMB?

Which has more risk and volatility, HYPD or CMMB?

Is HYPD or CMMB more profitable?

Which has higher valuation & earnings, HYPD or CMMB?

Do insiders and institutionals hold more shares of HYPD or CMMB?

Does the media refer more to HYPD or CMMB?

Summary

How does Chemomab Therapeutics compare to CervoMed?

Do insiders & institutionals have more ownership in CRVO or CMMB?

Which has more risk and volatility, CRVO or CMMB?

Do analysts rate CRVO or CMMB?

Does the media favor CRVO or CMMB?

Which has preferable earnings & valuation, CRVO or CMMB?

Is CRVO or CMMB more profitable?

Summary

How does Chemomab Therapeutics compare to ?

Does the media prefer or CMMB?

Do institutionals and insiders have more ownership in or CMMB?

Is or CMMB more profitable?

Do analysts recommend or CMMB?

Which has stronger valuation & earnings, or CMMB?

Summary

How does Chemomab Therapeutics compare to SCYNEXIS?

Do institutionals & insiders have more ownership in CMMB or SCYX?

Which has more volatility & risk, CMMB or SCYX?

Does the media prefer CMMB or SCYX?

Which has preferable earnings and valuation, CMMB or SCYX?

Is CMMB or SCYX more profitable?

Do analysts recommend CMMB or SCYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB vs. The Competition

Chemomab Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools